Your browser doesn't support javascript.
loading
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Madariaga, Ainhoa; Mitchell, Sandra A; Pittman, Tyler; Wang, Lisa; Bowering, Valerie; Kavak, Nisan; Quintos, Judy; Chang, Karen; Ramsahai, Janelle; Karakasis, Katherine; Welch, Stephen A; Dhani, Neesha C; Lheureux, Stephanie; Oza, Amit M.
Afiliación
  • Madariaga A; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; Autonomous University of Barcelona, Barcelona, Spain.
  • Mitchell SA; National Cancer Institute at the National Institutes of Health, Rockville, USA.
  • Pittman T; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Wang L; University of Toronto, Toronto, Ontario, Canada; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Bowering V; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Kavak N; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Quintos J; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Chang K; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Ramsahai J; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Karakasis K; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Welch SA; Division of Medical Oncology & Hematology, London Health Science, London, Ontario, Canada.
  • Dhani NC; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada.
  • Lheureux S; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada.
  • Oza AM; Division of Medical Oncology & Hematology, Bras Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada. Electronic address: amit.oza@uhn.ca.
Gynecol Oncol ; 167(2): 226-233, 2022 11.
Article en En | MEDLINE | ID: mdl-36055813
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Gemcitabina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2022 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Gemcitabina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2022 Tipo del documento: Article País de afiliación: España